No-One’s in Charge of Medicines in Europe! Last week’s story Who’s in charge of Medicines in Brussels? has been overtaken by history, with the departure of Guido Rasi from his post of Executive Director of the European Medicines Agency, writes Peter O’Donnell. At a time of flux in the European context for pharmaceuticals, Rasi’s moderate manner and capacity for strategic thinking were one reassurance amid so much uncertainty and his removal is to be lamented... Read more
Health 2.0: HCP Apps Steal the Show Two of the industry's most influential conferences— TEDMED (Washington, DC) and Health 2.0 (San Francisco, CA) — occurred within weeks of each other this autumn. Pharm Exec Editorial Advisory Board member Bill Drummy was at both events and found the major trends remarkably easy to see... Read more
Merck KGaA CEO Talks IP and Access to Medicines Speaking as he accepted the two-year role as president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in New York this month, Merck KGaA’s Stefan Oschmann called for more health innovation through local entrepreneurship and strongly denounced the argument that intellectual property is a hindrance to access to medicines... Read more
Pharm Exec’s 2015 Pipeline Report This year's pipeline report checks in on the emerging technologies, as well as potential therapies to address metabolic and neurodegenerative diseases. There's a lot to like in the pipeline and more than a little competitive drama to make it really interesting. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers? .... Read more
Which of the following activities is your most important upcoming initiative?
